DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival

Karina Dahl Steffensen, Marianne Waldstrøm, Anders Jakobsen

.

DOI: 10.4236/jct.2011.22016                

Abstract

Objectives: Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. Two single nucleotide polymorphisms (SNPs) of the ERCC1 gene, codon 118 C/T and C8092A, have been reported to be functional, but the influence on platinum resistance and survival is not yet clear. The primary aim of the present study was to investigate whether the two SNPs were associated with resistance to standard combination carboplatin and paclitaxel chemotherapy and the potential prognostic impact in newly diagnosed ovarian cancer patients. Methods: Serum samples from 202 patients with newly diagnosed ovarian cancer were assessed for ERCC1 SNP genotyping using real time PCR. All patients were treated with first line carboplatin/paclitaxel chemotherapy. Results: There were no correlation between the ERCC1 118 C/T and C8092A genotypes and platinum resistance (P = 0.79 and P = 0.36, respectively). Furthermore, the results showed no association to progression free survival (P = 0.18 and P = 0.16, respectively) or overall survival (P = 0.89 and P = 0.78, respectively) for the two SNPs. Conclusions: The ERCC1 118 C/T and C8092A polymorphisms did not have significant influence on clinical outcome defined as platinum resistance, PFS and OS.

Keywords

Drug Resistance, Ovarian Cancer, Polymorphisms, ERCC1, DNA Repair, Predictive MARKEr

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. T. Thigpen, “Chemotherapy for Advanced Ovarian Cancer: Overview of Randomized Trials,” Seminars in Oncology, Vol. 27, No. 3, June 2000, pp. 11-16.
[2]	C. A. Rabik and M. E. Dolan, “Molecular Mechanisms of Resistance and Toxicity Associated with Platinating Agents,” Cancer Treatment Reviews, Vol. 33, No. 4, February 2007, pp. 9-23. doi:10.1016/j.ctrv.2006.09.006
[3]	R. P. Perez, “Cellular and Molecular Determinants of Cisplatin Resistance,” European Journal of Cancer, Vol. 34, No. 10, September 1998, pp. 1535-1542. doi:10.1016/S0959-8049(98)00227-5
[4]	I. Díaz-Padilla and A. Poveda, “DNA Repair-Based Mechanisms of Platinum Resistance in Epithelial Ovarian Cancer: From Bench to Bedside,” Clinical Ovarian Cancer, Vol. 3, No. 1, May 2010, pp. 29-35. doi:10.3816/COC.2010.n.005
[5]	M. Dabholkar, L. Bradshaw, R. J. Parker, I. Gill, F. Bostick-Bruton, F. M. Muggia, et al., “Cisplatin-DNA Damage and Repair in Peripheral Blood Leukocytes in Vivo and in Vitro,” Environmental Health Perspectives, Vol. 98, November 1992, pp. 53-59. doi:10.1289/ehp.929853
[6]	E. Reed, “Platinum-DNA Adduct, Nucleotide Excision Repair and Platinum Based Anti-Cancer Chemotherapy,” Cancer Treatment Reviews, Vol. 24, No. 5, October 1998, pp. 331-344. doi:10.1016/S0305-7372(98)90056-1
[7]	S. De, I, P. J. McHugh, P. H. Clingen and J. A. Hartley, “Defining the Roles of Nucleotide Excision Repair and Recombination in the Repair of DNA Interstrand Cross-Links in Mammalian Cells,” Molecular and Cellular Biology, Vol. 20, No. 21, November 2000, pp. 7980-7990.
[8]	Q. Li, J. J. Yu, C. Mu, M. K. Yunmbam, D. Slavsky, C. L. Cross, et al., “Association between the Level of ERCC-1 Expression and the Repair of Cisplatin-Induced DNA Damage in Human Ovarian Cancer Cells,” Anticancer Research, Vol. 20, No. 2A, March 2000, pp. 645-652.
[9]	M. Dabholkar, F. Bostick-Bruton, C. Weber, V. A. Bohr, C. Egwuagu and E. Reed, “ERCC1 and ERCC2 Expression in Malignant Tissues from Ovarian Cancer Patients,” Journal of the National Cancer Institute, Vol. 84, No. 19, October 1992, pp. 1512-1517. doi:10.1093/jnci/84.19.1512
[10]	K. D. Steffensen, M. Waldstrom, U. Jeppesen, I. Brandslund and A. Jakobsen, “Prediction of Response to Chemotherapy by ERCC1 Immunohistochemistry and ERCC1 Polymorphism in Ovarian Cancer,” International Journal of Gynecological Cancer, Vol. 18, No. 4, October 2007, pp. 702-710.
[11]	K. D. Steffensen, M. Waldstrom and A. Jakobsen, “The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer,” International Journal of Gynecological Cancer, Vol. 19, No. 5, July 2009, pp. 820-825. doi:10.1111/IGC.0b013e3181a12e09
[12]	K. V. Ferry, T. C. Hamilton and S. W. Johnson, “Increased Nucleotide Excision Repair in Cisplatin-Resistant Ovarian Cancer Cells: Role of ERCC1-XPF,” Biochemical Pharmacology, Vol. 60, No. 9, November 2000, pp. 1305-1313. doi:10.1016/S0006-2952(00)00441-X
[13]	D. J. Park, W. Zhang, J. Stoehlmacher, D. Tsao-Wei, S. Groshen, J. Gil, et al., “ERCC1 Gene Polymorphism as a Predictor for Clinical Outcome in Advanced Colorectal Cancer Patients Treated with Platinum-Based Chemotherapy,” Clinical Advances in Hematology and Oncology, Vol. 1, No. 3, March 2003, pp. 162-166.
[14]	M. R. Shen, I. M. Jones and H. Mohrenweiser, “Nonconservative Amino Acid Substitution Variants Exist at Polymorphic Frequency in DNA Repair Genes in Healthy Humans,” Cancer Research, Vol. 58, No. 4, February 1998, pp. 604-608.
[15]	J. J. Yu, C. Mu, K. B. Lee, A. Okamoto, E. L. Reed, F. Bostick-Bruton, et al., “A Nucleotide Polymorphism in ERCC1 in Human Ovarian Cancer Cell Lines and Tumor Tissues,” Mutation Research, Vol. 382, No. 1-2, September 1997, pp. 13-20.
[16]	J. S. Ryu, Y. C. Hong, H. S. Han, J. E. Lee, S. Kim, Y. M. Park, et al., “Association between Polymorphisms of ERCC1 and XPD and Survival in Non-Small-Cell Lung Cancer Patients Treated with Cisplatin Combination Chemotherapy,” Lung Cancer, Vol. 44, No. 3, June 2004, pp. 311-316. doi:10.1016/j.lungcan.2003.11.019
[17]	J. J. Yu, K. B. Lee, C. Mu, Q. Li, T. V. Abernathy, F. Bostick-Bruton, et al., “Comparison of Two Human Ovarian Carcinoma Cell Lines (A2780/CP70 and MCAS) that are Equally Resistant to Platinum, but Differ at Codon 118 of the ERCC1 Gene,” International Journal of Oncology, Vol. 16, No. 3, March 2000, pp. 555-560.
[18]	C. J. McGurk, M. Cummings, B. Koberle, J. A. Hartley, R. T. Oliver and J. R. Masters, “Regulation of DNA Repair Gene Expression in Human Cancer Cell Lines,” Journal of Cellular Biochemistry, Vol. 97, No. 5, April 2006, pp. 1121-1136. doi:10.1002/jcb.20711
[19]	P. Chen, J. Wiencke, K. Aldape, A. Kesler-Diaz, R. Miike, K. Kelsey, et al., “Association of an ERCC1 Polymorphism with Adult-Onset Glioma,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 9, No. 8, August 2000, pp. 843-847.
[20]	G. J. Rustin, “Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials,” Journal of Clinical Oncology, Vol. 21, No. 10, May 2003, pp. 187-193. doi:10.1200/JCO.2003.01.223
[21]	G. J. Rustin, M. Quinn, T. Thigpen, B. A. du, E. Pujade-Lauraine, A. Jakobsen, et al., “Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer),” Journal of the National Cancer Institute, Vol. 96, No. 6, March 2004, pp. 487-488. doi:10.1093/jnci/djh081
[22]	M. Stephens, N. J. Smith and P. Donnelly, “A New Statistical Method for Haplotype Reconstruction from Population data,” The American Journal of Human Genetics, Vol. 68, No. 4, April 2001, pp. 978-989. doi:10.1086/319501
[23]	M. Stephens and P. Scheet, “Accounting for Decay of Linkage Disequilibrium in Haplotype Inference and Missing-Data Imputation,” The American Journal of Human Genetics, Vol. 76, No. 3, March 2005, pp. 449-462. doi:10.1086/428594
[24]	W. Zhou, S. Gurubhagavatula, G. Liu, S. Park, D. S. Neuberg, J. C. Wain, et al., “Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy,” Clinical Cancer Research, Vol. 10, No. 15, August 2004, pp. 4939-4943. doi:10.1158/1078-0432.CCR-04-0247
[25]	T. Takenaka, T. Yano, C. Kiyohara, N. Miura, H. Kouso, T. Ohba et al., “Effects of Excision Repair Cross-Com- plementation Group 1 (ERCC1) Single Nucleotide Polymorphisms on the Prognosis of Non-Small Cell Lung Cancer Patients,” Lung Cancer, Vol. 57, No. 1, April 2010, pp. 101-107.
[26]	S. Smith, D. Su, Rigault de la Longrais IA, P. Schwartz, M. Puopolo, T. J. Rutherford, et al., “ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit from Paclitaxel Treatment in Addition to Platinum-Based Therapy,” Journal of Clinical Oncology, Vol. 25, No. 33, November 2007, pp. 5172- 5179. doi:10.1200/JCO.2007.11.8547
[27]	S. Marsh, J. Paul, C. R. King, G. Gifford, H. L. McLeod and R. Brown, “Pharmacogenetic Assessment of Toxicity and Outcome after Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer,” Journal of Clinical Oncology, Vol. 25, No. 29, October 2007, pp. 4528-4535. doi:10.1200/JCO.2006.10.4752
[28]	H. S. Kim, M. K. Kim, H. H. Chung, J. W. Kim, N. H. Park, Y. S. Song, et al., “Genetic Polymorphisms Affecting Clinical Outcomes in Epithelial Ovarian Cancer Patients Treated with Taxanes and Platinum Compounds: A Korean Population-Based Study,” Gynecologic Oncology, Vol. 113, No. 2, May 2009, pp. 264-269. doi:10.1016/j.ygyno.2009.01.002
[29]	T. C. Krivak, K. M. Darcy, C. Tian, D. Armstrong, B. E. Baysal, H. Gallion, et al., “Relationship between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer,” Journal of Clinical Oncology, Vol. 26, No. 21, July 2008, pp. 3598-3606. doi:10.1200/JCO.2008.16.1323
[30]	S. Kang, W. Ju, J. W. Kim, N. H. Park, Y. S. Song, S. C. Kim, et al., “Association between Excision Repair Cross-complementation Group 1 Polymorphism and Clinical Outcome of Platinum-Based Chemotherapy in Patients with Epithelial Ovarian Cancer,” Experimental and Molecular Medicine, Vol. 38, No. 3, June 2006, pp. 320-324.
[31]	A. Kalikaki, M. Kanaki, H. Vassalou, J. Souglakos, A. Voutsina, V. Georgoulias, et al., “DNA Repair Gene Polymorphisms Predict Favorable Clinical Outcome in Advanced Non-Small-Cell Lung Cancer,” Clinical Lung Cancer, Vol. 10, No. 2, March 2009, pp. 118-123. doi:10.3816/CLC.2009.n.015